HIMS

HIMS

USD

Hims & Hers Health Inc. Class A Common Stock

$44.070-1.680 (-3.672%)

Prix en Temps Réel

Healthcare
Drug Manufacturers - Specialty & Generic
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$45.750

Haut

$48.340

Bas

$43.620

Volume

36.16M

Fondamentaux de l'Entreprise

Capitalisation Boursière

10.0B

Industrie

Drug Manufacturers - Specialty & Generic

Pays

United States

Statistiques de Trading

Volume Moyen

28.91M

Bourse

NYQ

Devise

USD

Intervalle sur 52 Semaines

Bas $19.15Actuel $44.070Haut $72.98

Actualités Connexes

Analyst Upgrades

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32

B of A Securities analyst Allen Lutz maintains Hims & Hers Health with a Underperform and raises the price target from $28 to $32.

Voir plus
B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32
Reuters

Futures tumble after Wall St banks warn of market pullback, Palantir slides

U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.

Voir plus
Futures tumble after Wall St banks warn of market pullback, Palantir slides
Analyst Upgrades

BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target

BTIG analyst David Larsen reiterates Hims & Hers Health with a Buy and maintains $85 price target.

Voir plus
BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target
Reuters

Hims and Hers beats revenue estimates on strong subscriber growth

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings.

Voir plus
Hims and Hers beats revenue estimates on strong subscriber growth
BusinessWire

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3

Voir plus
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
PR Newswire

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.

A securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) is pending. The lawsuit was filed by Glancy Prongay & Murray...

Analyst Upgrades

Keybanc Initiates Coverage On Hims & Hers Health with Sector Weight Rating

Keybanc analyst Justin Patterson initiates coverage on Hims & Hers Health with a Sector Weight rating.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.